You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BRAF585-614-V600E

Showing 1 - 25 of 597
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cancer Trial (Dabrafenib, Trametinib)

Not yet recruiting
  • Cancer
  • (no location specified)
May 25, 2023

Dabrafenib Plus Trametinib In Rare BRAF V600E Mutation-Positive

Not yet recruiting
  • Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
  • Non-investigational
  • (no location specified)
May 11, 2023

Aspirin in Combination With Trametinib and Dabrafenib

Not yet recruiting
  • NSCLC
  • +4 more
  • Combind asprin with Trametinib and Dabrafenib
  • (no location specified)
Aug 4, 2023

Colorectal Cancer, Colon Cancer, BRAF V600E Trial (Binimetinib)

Not yet recruiting
  • Colorectal Cancer
  • +4 more
  • (no location specified)
Aug 18, 2022

Colorectal Cancer, BRAF V600E Mutation Positive Trial (Encorafenib Oral Capsule + Cetuximab)

Not yet recruiting
  • Colorectal Cancer
  • BRAF V600E Mutation Positive
  • Encorafenib Oral Capsule + Cetuximab
  • (no location specified)
Jan 30, 2023

Colorectal Cancer Metastatic Trial (Tunlametinib plus Vemurafenib, Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy

Not yet recruiting
  • Colorectal Cancer Metastatic
  • Tunlametinib plus Vemurafenib
  • Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab
  • (no location specified)
Aug 15, 2023

Non Small Cell Lung Cancer Trial (HLX208+HLX10)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • HLX208+HLX10
  • (no location specified)
Nov 30, 2022

BRAF V600E Unresectable or Metastatic Melanoma, BRAF V600E Metastatic NSCLC, Melanoma Trial in Guangzhou (Encorafenib)

Completed
  • BRAF V600E Unresectable or Metastatic Melanoma
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Jun 9, 2022

BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer

Recruiting
  • Metastatic Non-small Cell Lung Cancer
  • BRAF V600 Mutation
    • Lyon, Rhône Alpes, France
      CHU Lyon - Hôpital Cardio-Vasculaire et Pneumologique Louis Prad
    Sep 14, 2022

    Non-small-cell Lung Cancer Trial (HL-085+Vemurafenib)

    Not yet recruiting
    • Non-small-cell Lung Cancer
    • (no location specified)
    Jun 8, 2023

    Metastatic Colorectal Cancer, mCRC Trial in Shenyang (HLX208)

    Recruiting
    • Metastatic Colorectal Cancer
    • mCRC
    • Shenyang, Liaoning, China
      Liaoning Cancer Hospital
    May 1, 2022

    Colorectal Cancer Trial in Shanghai (VIC, Bevacizumab Plus Chemotherapy)

    Recruiting
    • Colorectal Cancer
    • VIC
    • Bevacizumab Plus Chemotherapy
    • Shanghai, China
      Department of General Surgery, Zhongshan Hospital, Fudan Univers
    Sep 14, 2022

    Solid Tumor Trial in Toronto (Binimetinib, Encorafenib)

    Recruiting
    • Solid Tumor
    • Toronto, Ontario, Canada
      Princess Margaret Cancer Centre
    Sep 23, 2022

    CRC Trial in Shanghai (HLX208, Cetuximab Injection [Erbitux])

    Recruiting
    • CRC
    • HLX208
    • Cetuximab Injection [Erbitux]
    • Shanghai, China
      Fudan University Affiliated Oncology Hospital
    Dec 30, 2021

    Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Tumor in the Brain, Metastatic Malignant Tumor in the CNS

    Recruiting
    • Clinical Stage IV Cutaneous Melanoma AJCC v8
    • +3 more
    • Scottsdale, Arizona
    • +2 more
    Jan 4, 2023

    Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV Trial in Chicago

    Recruiting
    • Stage IV Colorectal Cancer Positive for BRAF V600E Mutation
    • +2 more
    • Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab
    • Chicago, Illinois
      Northwestern University
    Nov 16, 2022

    Melanoma Trial in Beijing (HL-085, Vemurafenib)

    Recruiting
    • Melanoma
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Apr 10, 2022

    BRAF NP_004324.2:p.V600X, KRAS wt Allele, Metastatic Malignant Solid Tumor Trial in Houston (biological, drug, other)

    Active, not recruiting
    • BRAF NP_004324.2:p.V600X
    • +6 more
    • Cetuximab
    • +4 more
    • Houston, Texas
      M D Anderson Cancer Center
    Sep 22, 2022

    NSCLC, Non-small Cell Carcinoma, Histiocytic Tumor Trial (BDTX-4933)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • +32 more
    • (no location specified)
    Mar 30, 2023

    BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Metastatic Thyroid Gland Carcinoma Trial in Portland (Binimetinib,

    Recruiting
    • BRAF NP_004324.2:p.V600M
    • +6 more
    • Portland, Oregon
      Providence Portland Medical Center
    Aug 17, 2022

    BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma Trial in Duarte, Columbus (Dabrafenib,

    Recruiting
    • BRAF NP_004324.2:p.V600E
    • +2 more
    • Duarte, California
    • +1 more
    Jan 19, 2023

    Langerhans Cell Histiocytosis, Erdheim-Chester Disease, LCH Trial in Beijing (HLX208)

    Recruiting
    • Langerhans Cell Histiocytosis
    • +3 more
    • Beijing, China
      Peking Union Medical College Hospital
    Dec 30, 2021

    Solid Tumor Trial in Guangzhou (HLX 208)

    Recruiting
    • Solid Tumor
    • HLX 208
    • Guangzhou, China
      Sun Yat-sen University Cancer Center
    Jan 26, 2022

    Anaplastic Thyroid Cancer, ATC Trial in Shanghai (HLX208)

    Recruiting
    • Anaplastic Thyroid Cancer
    • ATC
    • Shanghai, China
      Fudan University Affiliated Oncology Hospital
    Dec 30, 2021

    Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID

    Active, not recruiting
    • Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 9, 2022